ME00435B - Postupak za dobijanje derivata hinolina - Google Patents

Postupak za dobijanje derivata hinolina

Info

Publication number
ME00435B
ME00435B MEP-2008-656A MEP65608A ME00435B ME 00435 B ME00435 B ME 00435B ME P65608 A MEP65608 A ME P65608A ME 00435 B ME00435 B ME 00435B
Authority
ME
Montenegro
Prior art keywords
manufacture
quinoline derivatives
formula
quinoline
chaineded
Prior art date
Application number
MEP-2008-656A
Other languages
English (en)
French (fr)
Inventor
Karl Jansson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of ME00435B publication Critical patent/ME00435B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

Postupak za dobijanje jedinjenja opšte formule (I)   reakcijom derivata estra hinolin-3-karboksilne kiseline formule A   sa derivatom anilina formule B   u rastvaraču odbranom od alkana i cikloalkana sa pravim ili razgranatim lancem, ili njihove smeše, sa tačkom ključanja između 80 i 200°C.
MEP-2008-656A 2002-06-12 2003-05-14 Postupak za dobijanje derivata hinolina ME00435B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives
PCT/SE2003/000780 WO2003106424A1 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives

Publications (1)

Publication Number Publication Date
ME00435B true ME00435B (me) 2011-10-10

Family

ID=20288148

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-656A ME00435B (me) 2002-06-12 2003-05-14 Postupak za dobijanje derivata hinolina

Country Status (28)

Country Link
EP (1) EP1511732B9 (me)
JP (1) JP4584709B2 (me)
KR (1) KR100979216B1 (me)
CN (1) CN100418950C (me)
AT (1) ATE348814T1 (me)
AU (1) AU2003228195B2 (me)
BR (1) BR0311674A (me)
CA (1) CA2487329C (me)
CY (1) CY1107555T1 (me)
DE (1) DE60310554T2 (me)
DK (1) DK1511732T5 (me)
ES (1) ES2278160T3 (me)
HR (1) HRP20050028B1 (me)
IL (1) IL165155A (me)
IS (1) IS2975B (me)
ME (1) ME00435B (me)
MX (1) MXPA04012276A (me)
NO (1) NO329162B1 (me)
NZ (1) NZ536768A (me)
PL (1) PL210259B1 (me)
PT (1) PT1511732E (me)
RS (1) RS51021B (me)
RU (1) RU2291861C2 (me)
SE (1) SE0201778D0 (me)
SI (1) SI1511732T1 (me)
UA (1) UA78310C2 (me)
WO (1) WO2003106424A1 (me)
ZA (1) ZA200409430B (me)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
WO2007047863A2 (en) * 2005-10-19 2007-04-26 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
DK2035001T3 (da) 2006-06-12 2012-02-27 Teva Pharma Stabile laquinimod-tilberedninger
EA200900749A1 (ru) 2006-11-28 2009-12-30 Валеант Фармасьютикалс Интернэшнл 1,4-диаминобициклические аналоги ретигабина как модуляторы калиевых каналов
PT2682120T (pt) 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
CN104311486A (zh) 2008-09-03 2015-01-28 泰华制药工业有限公司 2-羰基-1,2-二氢喹啉免疫功能调节剂
EP2376456A2 (en) * 2008-12-17 2011-10-19 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
PL2458992T3 (pl) 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
ME02495B (me) 2009-08-10 2017-02-20 Teva Pharma Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
AU2011223697B2 (en) 2010-03-03 2016-07-14 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
SG183512A1 (en) 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
WO2012004338A1 (en) * 2010-07-09 2012-01-12 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EA201390074A1 (ru) * 2010-07-09 2013-06-28 Тева Фармасьютикал Индастриз Лтд. 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
SG10201505236YA (en) 2010-07-09 2015-08-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CA2863409A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
JP2016514162A (ja) * 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
KR102533033B1 (ko) 2014-09-23 2023-05-15 액티브 바이오테크 에이비 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드
KR102525805B1 (ko) 2014-11-19 2023-04-25 액티브 바이오테크 에이비 백혈병 치료용 퀴놀린 카르복사미드
EP4114368A1 (en) 2020-03-03 2023-01-11 Active Biotech AB Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
JP2023535021A (ja) 2020-07-23 2023-08-15 イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム 骨髄増殖性腫瘍における新規治療用標的としてのｓ１００タンパク質
MX2023008016A (es) 2021-01-18 2023-07-13 Active Biotech Ab Tasquinimod o una sal farmaceutica aceptable para su uso en el tratamiento del sindrome mielodisplasico.
CA3218977A1 (en) 2021-05-25 2022-12-01 Hans Wannman A plurality of tasquinimod particles and use thereof
EP4363404A1 (en) 2021-07-02 2024-05-08 Active Biotech AB A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
DK1511732T5 (da) 2007-10-01
CY1107555T1 (el) 2013-03-13
RS51021B (sr) 2010-10-31
NO20045703L (no) 2004-12-29
AU2003228195A1 (en) 2003-12-31
WO2003106424A1 (en) 2003-12-24
RU2005100054A (ru) 2005-07-10
SI1511732T1 (sl) 2007-06-30
DE60310554D1 (de) 2007-02-01
JP2005535612A (ja) 2005-11-24
AU2003228195B2 (en) 2009-05-28
CN1659146A (zh) 2005-08-24
CN100418950C (zh) 2008-09-17
DE60310554T2 (de) 2007-11-29
NO329162B1 (no) 2010-08-30
RS107604A (en) 2007-02-05
MXPA04012276A (es) 2005-04-08
PL373817A1 (en) 2005-09-19
KR20050016537A (ko) 2005-02-21
IS7550A (is) 2004-11-24
ES2278160T3 (es) 2007-08-01
IS2975B (is) 2017-07-15
HRP20050028B1 (hr) 2013-07-31
KR100979216B1 (ko) 2010-08-31
IL165155A (en) 2009-11-18
SE0201778D0 (sv) 2002-06-12
PL210259B1 (pl) 2011-12-30
HRP20050028A2 (en) 2006-02-28
NZ536768A (en) 2006-10-27
EP1511732A1 (en) 2005-03-09
PT1511732E (pt) 2007-03-30
JP4584709B2 (ja) 2010-11-24
ZA200409430B (en) 2006-02-22
EP1511732B9 (en) 2008-11-12
DK1511732T3 (da) 2007-04-30
CA2487329C (en) 2010-11-16
BR0311674A (pt) 2008-01-08
CA2487329A1 (en) 2003-12-24
IL165155A0 (en) 2005-12-18
RU2291861C2 (ru) 2007-01-20
ATE348814T1 (de) 2007-01-15
EP1511732B1 (en) 2006-12-20
UA78310C2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
HRP20050028B1 (hr) Postupak za proizvodnju derivata kinolina
RS65604A (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
NO20055099L (no) Fremgangsmate for fremstilling av 5-(haloacetyl)-8-(substituert oksy)-(1H)-kinolin-2-oner
WO2003035668A3 (en) Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
HUP0301699A2 (hu) Imidazolil-anilin-származékok előállítása anilinek és azolok racionális ligandum-gyorsított Ullmann-kapcsolásával
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
MY141020A (en) Novel pparalpha and ppargamma agonists
NO20055924L (no) Metode for fremstilling av (2s)-3-(4- {2-[Amino]-2-Oksoetoksy}Fenyl)-2-Etoksypropansyrederivater
ES2161863T3 (es) Procedimiento de produccion de inhibidores de proteasa de vih.
WO2003080631A8 (en) Plasma carboxypeptidase b inhibitors
WO2003024913A1 (fr) Derives d'acides benzoiques substitues possedant une activite d'inhibition de nf-kb
MY145980A (en) Process for the preparation of poly(silyl esters)s, and their uses
NO20031046L (no) Fremgangsmåte for fremstilling av en substituert imidazopyridinforbindelse
AU5209600A (en) Orally active androgens
WO2003014094A3 (de) Heterocyclylarylsulfonamide
WO2001083423A3 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof
JPS55154950A (en) Novel carboxylic acid amide derivative
ES2184633A1 (es) Procedimiento para la preparacion de derivados de 4-(imidazol-1-il) bencenosulfonamida.
HUP0202296A2 (hu) Eljárás szubsztituált benzizotiazolszármazékok előállítására
DK1339768T3 (da) Coatinger bestående af specielle polyoler og oxalsyre
NO20044045L (no) Ny fremgangsmate
TH72657A (th) สารประกอบ